Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMCISION: Neoadjuvant Nivolumab +/- Ipilimumab in HNSCC
NCT03003637Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2017
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Feasibility of neoadjuvant immunotherapy at 2.5 years, Tumor tissue pathological response and 1 more. Started Feb 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03003637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03003637.